摘要
目的:探讨尿激酶型纤溶酶原激活因子受体在人脑胶质瘤发生发展中的作用及靶向阻断对胶质瘤生长的影响。方法:采用人脑胶质瘤细胞U87MG建立高度重复性原位裸小鼠人脑胶质瘤模型,皮下应用鼠PEG-uPA 1-48(300μg)或人PEG-uPA 1-48(300μg)或者二者联合(各100μg)每周2次。结果:对照组9周内死亡,人PEG-uPA 1-48治疗组12周内死亡,20周后有20%鼠PEG-uPA 1-48治疗组和80%联合治疗组生存。组织学检测显示鼠PEG-uPA 1-48治疗组和联合治疗组肿瘤组织血管密度、细胞增殖指数显著降低,肿瘤细胞凋亡指数显著增加。结论:uPAR在胶质瘤的恶性演进中起重要作用,Peg-uPA能有效抑制脑胶质瘤生长,对脑胶质瘤辅助治疗有用。
Objective ： To investigate the exact role of urokinase-type plasminogen activator receptor （u-PAR） in the development of glioma and the inhibition of glioma growth by uPAR ligands. Methods ： A highly reproducible or thotopic brain model has been established in nude mice using the human brain tumor cell line U87MG. Animals xenotransplanted with these tumor cells were treated twice a week subcutaneously with 300 μg/mouse of either mouse or human Peg-uPA 1-48 or a combination of 100 μg of each after the establishment of the tumors. Results ： Control animals died within 9 weeks and human Peg-uPA treated animals within 12 weeks from progressive tumor growth. Twenty percent of the mice treated with mouse Peg-uPA and 80% of the mice receiving the combination of both peptides survived over 20 weeks. Histological examination demonstrated a decreased vascularity and tumor cell proliferation, a increased tumor cell apoptosis. Conclusion ： uPAR plays a prodominant role in glioma progression. Peg-uPA can effectively inhibit brain glioma growth and might prove to be useful for adjuvant treatment of brain glioma.
出处
《河南医学研究》
CAS
2006年第1期1-9,共9页
Henan Medical Research
关键词
脑胶质瘤
尿激酶受体
治疗结果
血管生成
凋亡
urokinase receptor
brain glioma
angiogenesis
adhesion
apoptosis
dhesion
